A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

LESSONS LEARNED. Itacitinib in combination with nab‐paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity in patients with advanced solid tumors including pancreatic cancer. The results support future studies of itacitinib as a component of combination regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Beatty, Gregory L., Shahda, Safi, Beck, Thaddeus, Uppal, Nikhil, Cohen, Steven J., Donehower, Ross, Gabayan, Afshin Eli, Assad, Albert, Switzky, Julie, Zhen, Huiling, Von Hoff, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324630/
https://www.ncbi.nlm.nih.gov/pubmed/30115734
http://dx.doi.org/10.1634/theoncologist.2017-0665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324630/
https://www.ncbi.nlm.nih.gov/pubmed/30115734
http://dx.doi.org/10.1634/theoncologist.2017-0665

Ejemplares similares